生物技术与制药领域的最新动态
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Market, 2025-2033: Insights by Service, Product, End-Use and Region - ResearchAndMarkets.com - The AI Journal
Microsize Expands Global Footprint With Bold Move Into European Micronization - MyChesCo
Lonza’s Growth Hinges On Biologics, But Risks Remain - Finimize
How Lonza Group AG (Common Stock) (LO3A) stock behaves under inflation pressure - July 2025 Final Week & Risk Managed Investment Signals - Newser
How Lonza Group AG (Common Stock) (LO31) stock trades in high volatility - July 2025 News Drivers & Daily Technical Forecast Reports - Newser
What MACD trends signal for Lonza Group AG (Common Stock) (LO3A) stock - Trade Volume Summary & Short-Term High Return Ideas - Newser
Morgan Stanley Keeps Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
Biologics CDMO Market Trends and Investment Forecast to 2033: Features Analysis of Lonza Group, Cata - PharmiWeb.com
Lonza Group (OTCMKTS:LZAGY) Sees Strong Trading Volume - Time to Buy? - MarketBeat
Middle East Cell and Gene Therapy CDMO Market Forecast to 2033 Featuring Strategic Profiles of Key P - PharmiWeb.com
Will Lonza Group AG (Common Stock) (LO31) stock issue positive guidance - 2025 Price Targets & Risk Controlled Daily Plans - Newser
What MACD trends signal for Lonza Group AG (Common Stock) (LO3A) stock - Newser
Microsize, Schedio link to buy Lonza’s Swiss micronization plant - Fierce Pharma
We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt - simplywall.st
Why Lonza Group AG (LO3) stock is a must watch ticker - Market Growth Report & Capital Efficient Trade Techniques - moha.gov.vn
Innovation in action: Inside the technologies transforming bioavailability - nutritioninsight.com
Morgan Stanley upgrades Lonza Group stock to Overweight on growth outlook - Investing.com Australia
Morgan Stanley upgrades Lonza Group stock to Overweight on growth outlook By Investing.com - Investing.com South Africa
Morgan Stanley Upgrades Lonza Group to Overweight, Lifts PT - MarketScreener
Morgan Stanley upgrades Lonza, citing valuation support ahead of 2026 guide - Investing.com